ARTICLE | Top Story
bluebird, Celgene narrow CAR-T partnership
June 4, 2015 2:25 AM UTC
bluebird bio Inc. (NASDAQ:BLUE) and Celgene Corp. (NASDAQ:CELG) narrowed their 2013 multi-target partnership to develop chimeric antigen receptor (CAR) T cell therapies to focus on a single target: tumor necrosis factor (TNF) receptor superfamily member 17 ( TNFRSF17; BCMA; CD269). The collaboration will be extended for three years.
Under the amended collaboration, bluebird will receive $25 million upfront and lead R&D activities for lead program bb2121 and other anti-BCMA candidates through the completion of Phase I studies. bluebird expects to begin a Phase I trial of bb2121 next year to treat multiple myeloma. ...